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A B S T R A C T
Fungal infections include a wide range of opportunistic and invasive diseases. Two of four major fatal diseases in
patients with human immunodeficiency virus (HIV) infection are related to the fungal infections, cryptococcosis,
and pneumocystosis. Disseminated candidiasis and different clinical forms of aspergillosis annually impose ex-
pensive medical costs to governments and hospitalized patients and ultimately lead to high mortality rates.
Therefore, urgent implementations are necessary to prevent the expansion of these diseases. Designing an ef-
fective vaccine is one of the most important approaches in this field. So far, numerous efforts have been carried
out in developing an effective vaccine against fungal infections. Some of these challenges engaged in different
stages of clinical trials but none of them could be approved by the United States Food and Drug Administration
(FDA). Here, in addition to have a comprehensive overview on the data from studied vaccine programs, we will
discuss the immunology response against fungal infections. Moreover, it will be attempted to clarify the un-
derlying immune mechanisms of vaccines targeting different fungal infections that are crucial for designing an
effective vaccination strategy.
1. Introduction
Nowadays, the importance of preventive and treatment methods for
fungal infections is highlighted by increasing number of the high-risk
groups exposed to invasive fungal infections (IFIs), including cancer
patients under chemotherapy, bone marrow transplantation, acquired
immune deficiency syndrome patients (AIDS), and all other diseases
with immune deficiency following long-term hospitalizations [1,2]. IFIs
could also be found in patients treated with a wide range of antibiotics
and intravenously or intra-arterially catheter treatment methods [3], in
premature infants, and the hospitalized patients in intensive care units
[4]. Furthermore, 40% of patients with hematologic malignancies are
exposed to IFIs [5]. Very low birth weight (VLBW) infants are at high
risk to IFIs [6]. To prevent the expansion of IFIs, these infants require
extensive therapies, such as intravenous catheters, long-term antibiotic
regimes, and more importantly, postnatal steroid therapies. Most pre-
valent IFIs in VLBW infants are, Candida species (spp), Malassezia spp,
Aspergillus spp, and Zygomycetes [6]. It has been shown that Candida spp
are the fourth and first causative agents of nosocomial bloodstream
infections in the US and the European countries, respectively [7].
Furthermore, despite an experimental therapy, the mortality rate of
invasive candidiasis is about 30–40% [7]. HIV/AIDS patients show a
high mortality rate following opportunistic fungal infections. Crypto-
coccus neoformans (C. neoformans) is also a most common yeast that
infects these patients [8]. The outbreak of cryptococcosis in HIV/AIDS
patients was increased at the beginning of the 1990s in the US, before
the utilization of highly active antiretroviral therapy. Using this therapy
between 1993–2000, a 92% decrease in the outbreak rate of this in-
fection in HIV/AIDS patients was reported [9]. Generally, IFIs are re-
sponsible for 50% of the mortality cases which encompasses 1.5 million
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subjects per year. Such a high mortality rate is followed by nonspecific
clinical signs and symptoms, scarcity of the preventive methods, ap-
propriate diagnosis, and sufficient antifungal medicines [10]. Con-
sidering an increasing population of immunocompromised patients and
application of immunosuppressive treatments, we have been facing
with extremely dramatic increase in the life-threatening infections even
by the coexistent species, such as Candida albicans (C. albicans) [11].
Therefore, it is essential to review how the immune system controls the
fungal infection.
2. Immunology of fungal infections
2.1. Innate immunity
The frontline battlefield of the immune system with fungi pathogen
is the physical barriers, chiefly the skin and the mucosal epithelial
surfaces, existing in mouth, upper airways, and the gastrointestinal and
genitourinary tracts, which are constantly exposed to environmental
organisms [12]. Moreover, epithelial cells play pivotal roles in
launching the effective antifungal responses through discriminating
pathogenic and non-pathogenic fungal morphotypes [13,14].
The critical step in the initiation of an immune response is the re-
cognition of the specific components of fungi, called pathogen-asso-
ciated molecular patterns (PAMPs), by pattern recognition receptors
(PRRs) (Fig. 1). Different types of innate immune cells, including
macrophages (MQs) and dendritic cells (DCs) express a vast repertoire
of PRRs, such as Toll-like receptors (TLRs), C-type lectin receptors
(CLRs), NOD-like receptors (NLRs), and RIG-like receptors (RLRs) [15].
Among them, TLR2, TLR4, and Dectin-1 have prominent roles in de-
tecting fungal cell wall PAMPs. Previously we showed that TLR2 gene
expression increased in mice group with systemic candidiasis (SC) and
also in cyclophosphamide-dependent immunosuppressed mice with SC
[16]. However, our recently published data showed that TLR2 had no
significant role in launching the immune responses in im-
munosuppressed mice [17]. Phagocytic cells, MQs, DCs, and neu-
trophils, are able to recognize the fungi at the first stages of infection
through a variety of receptors (including PRRs) and combat with fungi
through phagocyting and releasing antimicrobial components, such as
oxygen radicals. Additionally, phagocytic cells are able to produce cy-
tokines, which induce the maturation of CD4+ T cells toward specific
subtypes (Fig. 2) [18–20].
Complement system and other humoral factors, such as antifungal
peptides, mannose-binding lectins (MBLs), defensins, and collectins also
provide fundamental defense mechanisms through opsonization of
fungi [12,19,21]. For example, recognition of deposited complement
particles on β-(1,6)- glucans of the fungus surface by complement re-
ceptor 3 (CR3; a heterodimer of CD11b and CD18 which is expressed on
different types of immune cells, such as neutrophils, monocyte/mac-
rophages, and natural killer (NK) cells) leads to elimination of patho-
gens by phagocytic cells [19], a process called opsonophagocytosis.
Defensins (which are secreted by the epithelium and paneth cells in gut)
and collectins are involved in opsonizing and also induction of in-
flammatory responses in collaborating with helper T (Th)-17 profile
cytokines (Fig. 2) [3].
2.2. Acquired immunity
In addition to recognizing different regions of fungal cells through
different types of PRRs, antigen-presenting cells (APCs), including DCs,
MQs, and B cells present the antigenic epitopes on major histo-
compatibility complex (MHC) class II or class I molecules (which are
expressed on APC surfaces) to CD4+ or CD8+ T cells, respectively
[17,22,23]. This way, these cells stimulate acquired immune response
(Fig. 2).
During this process, environmental cytokines produced at the site of
APC-T cell binding trigger the differentiation of CD4+ T cells into a
specific Th cell subtypes through activating different signaling path-
ways. STAT1/STAT4 transcription factors are needed for Th1 differ-
entiation, while STAT3/ROR-γt are required for Th17 development,
GATA3/STAT6 are involved in Th2 development (Fig. 2) [12,18,19,24].
If DCs (known as the major APC) release interleukin (IL)-12, the CD4+
T cells will be differentiated to Th1 cells. Different sets of immune re-
sponses will emanate from Th-triggered cytokines [19]. Th1 and Th17
cytokines, chiefly, gamma-interferon (IFN-γ) and IL-17, produce pro-
tective and protective-inflammatory responses, respectively [25,26].
More precisely, IFN-γ induces cell-mediated immunity through stimu-
lating phagocytes and Th17 cells release IL-17 and IL-22 cytokines that
initiate the neutrophilic response and release antimicrobial peptides
peptides like defensins to the site of infection [27]. Finally, at the end
stages of immune responses, Foxp3+/CD4+ T cells, which are called
regulatory T (Treg) cells, release the transforming growth factor (TGF)-
β and IL-10 in order to repress the elevated levels of inflammatory re-
sponses (Fig. 2) [28].
Fig. 1. Signaling pathway illustration
during fungal sensing and processing.
Following PAMP-PRR interaction, CTKs phos-
phorylate both central tyrosine of ITAM and
also protein adaptors which triggers the further
stimulation of downstream signaling mediators
and eventually leads to the production of pro-
inflammatory cytokines and other soluble
mediators through activation of TFs. CTK; cy-
toplasmic tyrosine kinase. ITAM; im-
munoreceptor tyrosine-based activation motif.
TFs; transcription factors.
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3. Fungal vaccines/main categories
Based on the analysis of different kinds of vaccines against in-
fectious agents, it has been reported that vaccines annually prevent 6
million deaths all around the world [29]. The aim of this review is
providing the comprehensive review of antifungal vaccines and their
immune mechanisms. Here, different kinds of vaccines which are used
for prevention of fungal infections are classified into three main groups.
We discuss live-attenuated, recombinant, and conjugate vaccines
(Fig. 3). Finally, almost all of the studied anti-fungal vaccine programs
are gathered and presented in Table 1 to form an overall view.
3.1. Live-attenuated vaccines
According to the similarity of live-attenuated vaccines with in-
fectious agents, they launch long-term and strong immune responses,
which can be efficient in the immunocompetent patients. However,
consideration of the precautionary aspects seems to be necessary.
Vaccinologists have designed several products of live-attenuated vac-
cine strategies, which are very efficacious to combat with highly-in-
fectious disease, mainly infectious viruses containing influenza, polio,
mumps, rubella, measles, varicella, and rotavirus [30]. During infection
with different pathogenic fungi, such as Histoplasma capsulatum (H.
capsulatum), Blastomyces dermatitidis (B. dermatitidis), Paracoccidioides
brasiliensis (P. brasiliensis), Pneumocystis carinii (P. carinii), and C. neo-
formans, these strategies are highly effective through triggering
Fig. 2. Immune responses induced by fungus or vaccine-related antigens. After the failure of epithelial surfaces, as the first defense line against fungal in-
fections, the immune response starts a new phase. Following the PRRs (TLRs, Dectins, Galectin-3, Mannos receptors, DC-SIGN, and Mincle) and PAMPs interaction,
some specific signaling pathways are stimulated in the APC, eventually leading to the production of different cytokines. In this regard, the protein adaptors, such as
MyD88, Syk, RAS, and TRIF are activated through connecting to the cytoplasmic stimulatory domain of PRRs (such as TIR for TLRs), which then trigger the
downstream adaptor proteins (CARD-9, BCL-10, MALT-1, IRAK-1, IRAK-4, TRAF-6, and RAF-1). This, in turn, ultimately activate the transcription factors (NF-kB, AP-
1, IRF-3, and IRF-7), resulting in the production of cytokines. Moreover, Dectin-1 is able to stimulate the inflammasomes (consisted of different adapter proteins) and
finally triggers Caspase-8 and Caspase-1, which catalyze the production of IL-1β from pro-IL-1β. At the next step, the processed antigen in the APC (chiefly DCs) are
presented to naive T cells. According to the cytokines resulted from PAMP-PRR interaction, the class of T cell is formed. For example, IL-23, IL-6, and TGF-β trigger
the stimulation of the Th1 profile (through T-bet, STAT1, and STAT4 transcription factors) that induce the Th17 cytokines, such as IL-17 and IL-21, which are the
main players of inflammatory response. B cell responds to fungal antigens through two different ways. One is through T-independent (TI) response against non-
protein antigens (polysaccharides, lipids, glycolipids, acid nucleic). Due to the absence of T cell responses, no immunological memory, secondary response, affinity
maturation, and isotype switching (usually conducted by cytokines of T cell) are occurred, eventually leading to the production of IgM isotype antibodies with low-
affinity and low half-life. B cell also responds to protein antigens through the T-dependent (TD) immunity. The processed antigen is presented to the CD4+ T cell by
MHC class II molecules and CD40-CD40 L (CD154) interaction. Following the activation of CD4+ T cells, the desired help package is released (consisting different
cytokines and molecules) to the B cells. Afterwards, B cell responds to the help through triggering the specific signal transduction, which eventually leads to the
production of various antibody isotypes (isotype switching) with high affinity (affinity maturation) and high half-life. This also includes the immunological memory
and secondary responses. Nowadays, TD immunization is followed by many research projects (subunit and conjugate vaccines) through binding fungal poly-
saccharides to the engineered/synthesized proteins.
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protective immune responses via common pathways (Table 1) [30,31].
This type is the first vaccine used in human subjects. There are several
studies in this field evaluating the efficiency of killed and attenuated
fungi (Table 1). These vaccines will be applicable for endemic fungal
pathogen prevention in the future in subjects with healthy immune
system who live in endemic areas [32,33]. One important finding is the
heat-killed Saccharomyces cerevisiae (HKS) vaccine, which plays an
important role in protection against different fungal infections as a pan-
fungal vaccine plan (discussed below) [34,35]. Vaccination with HKS
through a subcutaneous route has been shown to be effective in pro-
tection against virulent strains of the endemic fungus Coccidioides po-
sadasii (C. posadasii) [32], C. albicans [35] and Aspergillus fumigatus (A.
fumigatus) [35]. In addition, a study reviewed the clinical efforts about
developing of whole recombinant S. cerevisiae-based therapeutic
method for the treatment of cancer and viral diseases together with
cytotoxic drugs to achieve more clinical responses [36]. One major
issue is the specificity of the vaccine, which limits the spectrum of its
effects [34].
Formalin-killed Coccidioides immitis (C. immitis) spherules (FKS) is
another vaccine type in this category. Previously, a placebo-controlled
phase III trial has been carried out to evaluate the efficacy of FKS that
was unsuccessful to prevent the harshness of infection [36]. Later, a
study showed that vaccination (subcutaneously or by oral gavage with
or without adjuvants) with HKS protected 100% of CD1 mice from a
lethal C. immitis challenge through prolonging survival and reducing
fungal burden. Oral live Saccharomyces, but not HKS, prolonged sur-
vival without reduction in fungal burden. Survival of mice given HKS
was equal with FKS. This study indicates that HKS was superior to a
successful recombinant vaccine with adjuvant [32]. Moreover, a study
showed promising results of subcutaneous immunization of mice model
with an attenuated strain of C. posadasii [33]. This strain was unable to
transform to pathogenic spherule form and endosporulation process,
following deletion of two chitinase genes.
Deletion of Blastomyces adhesion 1 (BAD-1) gene presents an atte-
nuated vaccine which has been shown to recruit multiple arms of the
host immune response (Fig. 2) [37–40]. A study tested an immunization
plan for the BAD-1 vaccine in CD4+ T cell deficient host like HIV/AIDS
patients. In the absence of T helper cells, fungal PAMPs activate
memory CD8+ cells via interaction between MHC class I and CD8+ T
cell that leading to secretion of their cytokines, such as tumor necrosis
factor (TNF)-α, IFN-γ, and granulocyte/macrophage colony-stimulating
factor (GMCSF). This study indicates that CD8+ T cells could also rely
on alternate mechanisms for robust vaccine immunity against experi-
mental fungal pulmonary infections with two agents, B. dermatitidis
and H. capsulatum [41]. In the same framework, the genetically en-
gineered BAD-1 attenuated strain has also been tested that eventually
leads to the failure in binding or entry of yeasts into macrophages and
adherence to lung tissue, and also reduction of virulence in mice. [42].
Another study showed that subcutaneous administration of the BAD-1
live yeast without any adjuvant elevated the survival rate of mice from
lethal challenge of B. dermatitidis [43]. Mice immunized with re-
combinant BAD-1 yeasts, alone or in combination with IL-12 as an
adjuvant, showed acceptable efficacy in launching immune responses
(Fig. 2) [44,45].
Another attenuated vaccine strategy, which is named H99 g, has
previously been shown to protect CD4+ T cell-deficient mice from in-
fection with a virulent strain of C. neoformans through inducing murine
IFN-γ and Th1 responses [46]. The H99 g strain is regarded as a live
vaccination plan which is a potent stimulator of host cytokine pro-
duction and, therefore, could not be usable in human subjects. A similar
work reported the critical role of both CD4+ and CD8+ T cells in the
protection of mice against C. neoformans infection [47]. The safety of
attenuated vaccines in the immunosuppressed hosts has not been
guaranteed. But these two recent strategies (BAD-1 and H99 g) may
immunize the CD4+ T cell-deficient subjects, particularly HIV/AIDS
patients [48].
As a first live attenuated plan, a vaccine was designed for the pre-
vention of ringworm caused by Trichophyton verrucosum (T. verrucosum)
in cattle [30,49]. This study was carried out in a 5-year period on over
than 400,000 cattle and demonstrated the efficacy of this immuniza-
tion-immunoprophylaxis strategy. The results of these studies clear the
perspectives about the future utilization of antifungal vaccines for
subjects with CD4+ T cell deficiencies, such as patients with HIV in-
fection.
The main challenge is that the application of attenuated vaccines
should not lead to other kinds of diseases in immunosuppressed pa-
tients.
Fig. 3. Three main category of vaccine against fungi.
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3.2. Recombinant (subunit) vaccines
Subunit vaccines are the most investigated sorts of fungal vaccines
that consist of one or more purified recombinant proteins or poly-
saccharides of fungi. Genetic engineering and also increased knowledge
in the microbial pathogenesis and fundamentals of immunology help
scientists to develop efficient subunit vaccines. Scientific basis of this
technology is transferring and expressing of a gene encoding an im-
munogenic antigen, in order to trigger the desired immune response. In
fact, in this approach, a gene which is transmitted encodes a portion
related to virulence and pathogenicity of organism. These protein an-
tigens are often combined with an appropriate adjuvant or protein
carrier, mostly bacterial toxoids, to establish an efficient immune re-
sponse and prolonged immunization (Fig. 2) [31,48,50]. Alum (alu-
minum salts, such as aluminum hydroxide and aluminum phosphate) is
one of the most common adjuvants in this field which induces strong
antibody responses [48,51,52]. Recombinant subunit vaccines has
several advantages, such as absence of the pathogenic agent and,
therefore, application of these vaccines becomes safer particularly in
immunocompromised patients [48,53]. By merging the DNA en-
gineering and recombination technologies, vaccines have been carefully
designed, purified, and produced, which leads to the engineering of
highly specialized antigens [54,55].
A study showed that an invasion protein, agglutinin-like sequence 3
(Als3p) conjugated with alum, which is called NDV-3, conferred anti-
Candida protection through preventing yeast-epithelial/endothelial
attachment [56]. In addition, NDV-3 induced a cross-protection against
highly infectious bacterial pathogens, such as Staphylococcus aureus (S.
aureus) due to the structural homology between Als3p and clumping
factor-A of S. aureus. Most importantly, NDV-3 successfully passed the
phase I clinical trial and was found to be safe and protective in human
subjects through triggering the antigen-specific T cells that released
IFN-γ and IL-17 A cytokines [57]. This vaccine has also been approved
to elicit a protection in animal models of oropharyngeal, vaginal, and
invasive candidiasis [48,58,59].
Another study showed that secreted aspartyl proteinase-2 (Sap-2), a
highly expressed virulence factor secreted by different Candida spp,
displayed protective roles against recurrent vaginal candidiasis in a
virosome-based format of the vaccine [48,60]. This vaccine was applied
in the rat model of vaginal candidiasis and also a phase I clinical trial
and showed effective results [48,60]. However, there are several pro-
blems in the commercialization of recombinant vaccines, such as
healthy status of a subject (both immunocompromised and im-
munocompetent hosts), economic issues in targeting the human subject
(high costs of application in clinical trials), and also the method of
synthesis of the vaccine, such as glycosylation, which directly affects
the immunization circumstances [48,61,62].
3.3. Conjugate vaccines
A conjugate vaccine is produced by covalent attaching of a poor
antigen to a strong antigen, commonly polysaccharide to protein, re-
spectively. This is carried out in order to generate a potent immune
response [63]. B cells, in confronting with polysaccharide antigens,
develop antibody responses without contribution of T cells, which is
called T-independent immune response. In fact, polysaccharide epi-
topes are recognized by B cell receptors, but for the presentation of
antigens to T cells, they should bind to peptides (hapten-carrier system)
and the peptide is required to be presented by MHC complexes ex-
pressed on the APCs. Immunity stimulated by T cells is a strong and
durable. Through conjugating a polysaccharide to a protein carrier,
MHC molecules are able to bind proteins and eventually induce the T
cell responses (Fig. 2) [48,64].
One major advantage of conjugate vaccine strategy is that these
vaccines are based on targeting the polysaccharide epitopes, which are
common in all fungi, especially β-glucans. Therefore, this technique
could be applicable to produce and commercialize pan-fungal vaccines.
This is very crucial for immunosuppressed patients which are at high
risk for various form of IFIs [63,65].
The first fungal conjugate vaccine was designed against C. neofor-
mans that contained glucuronoxylomannan (GXM), a capsular poly-
saccharide, and tetanus toxoid (TT) [66]. These two particles are linked
by a covalent bond and a monophosphoryl lipid A (MPL) is used as an
adjuvant in the vaccine complex. Immune mechanism of this vaccine is
based on the antibody (especially IgA and IgG) responses. Additionally,
a pan-fungal vaccine, designed by conjugating a β-glucan poly-
saccharide extracted from brown algae, to inactivated diphtheria toxin
(CRM) and complete freund's adjuvant (CFA), showed effective roles in
protection against invasive candidiasis and aspergillosis [67]. Another
conjugate anti-Candida vaccine was constructed by conjugating β-1,2-
mannotriose to a peptide segment from fructose-bisphosphate aldolase
(Fba), which is the surface antigens of Candida spp. Various forms of
this vaccine have been applied in different studies (with or without
alum adjuvant) [68] (see Table 1).
4. Novel strategies
4.1. DNA vaccines
By entering the cDNA encoding the desired antigen into a plasmid
and transferring the gene containing plasmid to the host's APCs (mainly
DCs), the antigen is expressed and eventually generates a desired im-
mune response. Bacterial plasmids contain non-methylated CpGs,
which are recognized by TLR9 (expressed on DCs), and further stimu-
late the acquired immune responses. In addition to the antigen coding
gene, the gene which codes the co-stimulatory molecules and also cy-
tokines can join to the plasmids. This vaccine could also be applied
without any adjuvant. However, despite the current theories on safety,
immunogenicity, and efficacy, the application of this type of vaccine for
human faced with some major challenges [30,69]. Previously, DNA
vaccines have also been examined through transferring one or more
antigen coding plasmids [70–72]. The first fungal DNA vaccine may be
related to ringworm caused by T. verrocosum, which was discussed
above [49].
4.2. Immunotherapeutic products
Two novel vaccine strategies share immunotherapeutic nature
based on the application of fungus antigen-primed DCs and/or fungus-
specific T cell clones [31,73,74]. In these programs, fungus-protective
antigens were identified, regenerated, primed to the DCs ex vivo, and
eventually infused to the host in order to selective priming-activation of
DCs and formation of highly specific T cell clones. Immune responses
produced by these strategies have clearly potent effects and precision.
Romani and colleagues described the benefits of these approaches
[31,73,74].
4.3. Pan-fungal vaccine strategy
Fungal cell wall contains common epitopes. By inactivating and
conjugating the fungal common polysaccharides with different im-
munogenic peptides, we are able to form a type of vaccine which
protects the host from different types of fungal infections. Nowadays,
two pan-fungal vaccine plans have been developed. Killed S. cerevisiae
triggers the protective immune response against glucans and mannans,
which are common fungal polysaccharide epitopes. This vaccine also
launches the cross-reactive immune responses against homologous
proteins which exist on the fungal cell walls [34]. Another universal
vaccine strategy is made up from conjugating β-glucans to an in-
activated version of diphtheria toxin (CRM), which was mentioned
above [67].
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5. Vaccine based immunity against fungal infections
One of the most interesting and fascinating topics is to predict the
immune responses before and after exposure to the vaccine agent in
both healthy and infected hosts. In other words, each vaccine stimulates
the immune responses through different and more-specified ways,
which scrutinizing them is one major point in progressing the vaccine
strategies against fungal infections. We previously discussed the im-
mune responses against fungi. Totally, T cell-mediated responses are
the main arms of the immune response in combating fungi.
Furthermore, there are several cellular (macrophages, neutrophils) and
soluble (antimicrobial peptides, cytokines, and chemokines) tools.
Vaccines not only launch but also amplify the immune responses, par-
ticularly the vaccines used in conjugation with an adjuvant. Some of the
antifungal vaccines enhance antibody responses and others mostly in-
tensify Th responses. But most of them simultaneously boost both types
of immune responses (Fig. 2). The immune responses used for each
vaccine are extracted and listed in Table 1. Here, we review the me-
chanisms of some important vaccines.
5.1. Antibody mediated vaccine responses
Studies showed that specific antibodies cause protection against C.
neoformans by triggering classical opsonophagocytosis, complement
activation, and direct neutralization of adhesins or enzymes, which are
totally humoral immunity [62,75]. There are several studies about
antibody-mediated immunity to fungal infections induced by passive
vaccination strategies (Table 1). The immune mechanism emerged from
NDV3 and above discussed conjugate vaccine for cryptococcosis [66]
are based on IgG and IgA antibodies. Alum adjuvant is also a potent
stimulator of antibody responses (discussed above).
5.2. Th mediated vaccine responses
Th1/Th17 profiles play major roles in eliciting protective/in-
flammatory responses, which are triggered by different types of fungal
vaccines (Fig. 2). Therefore, vaccinologists have focused on this field
more precisely. A lot of studies in this field showed that the IFN-γ/IL-17
responses and also other receptors and cytokines, which are crucial for
Th1 and Th17 responses, play pivotal roles in vaccine mechanisms. For
example H99 g induces Th1 profile cytokines, chiefly IFN-γ [46], and
another vaccines triggering both CD4+ and CD8+ T cells (discussed
above) [47]. Predominanly, these studies have been conducted more
specifically for candidiasis and aspergillosis [76], which indicated that
Th1/Th17 mediated immunity by vaccines are far important than other
factors, such as neutralizing antibodies. DNA vaccines are able to sti-
mulate both CD4+ and CD8+ T cell responses through the MHC class I
and MHC class II pathways (Fig. 2). They also activate the phagocytic/
cytotoxic effectors and humoral responses. Another interesting topic in
this area is the upgraded collaboration between Th17 and neutralizing
antibodies by different types of the vaccines [76–78]. As discussed
above, the subunit vaccines are typical examples of the vaccines that
induce multiple immune responses, including T cells and antibodies.
Almost all of the existing vaccines mediate the protection through both
Th17 and neutralizing antibody-mediated mechanisms [79].
6. Conclusion
In recent decades, a wide range of studies tested vaccines for fungal
infections, such as Candida spp, Pneumocystis jiroveci/carinii, A. fumi-
gatus, and C. neoformans. But there are a lot of limitations in this field.
The main limitation is the emerging of IFIs in patients with immune
deficiency who are not able to produce effective response against vac-
cines. Another limitation is triggering the allergic responses by specific
vaccines in sensitive people [65,80]. However, some studies carried out
on the endemic fungal infections, histoplasmosis, blastomycosis,
coccidioidomycosis, and paracoccidioidomycosis [2]. In the 1980s,
clinical trials were conducted on the coccidioidomycosis vaccines and
these trials have continued until now [81]. Apart from all these efforts
for producing a suitable vaccine with active or passive immunization,
none of the fungal vaccines have been confirmed by FDA.
The first step in designing an effective strategy for vaccination
against fungal infections is to improve our knowledge of the immune
system. Following the profound knowledge of the mechanisms of im-
mune responses to fungal infections, it is possible to design and apply
the immunological products which termed immunotherapy. Immune
adjuvants, especially TLR-ligands, along with monoclonal antibodies
are the most important products of immunotherapeutics. Monoclonal
antibodies, in spite of high costs, shows acceptable results in conjunc-
tion with vaccines. Nowadays, this strategy is expanding by many re-
search projects. Targeting the pan-fungal antigens also presented ac-
ceptable results in the production of universal fungal vaccines.
However, application of new techniques, such as DNA vaccines and
immunotherapeutic products, with significant advances in the fields of
genomics, vaccinomics, and proteomics will be useful to open new
avenues for the success of vaccine strategies in clinical trials.
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